Liquid biopsy and the future of tumour-agnostic treatments
Liquid biopsy-based tools are positioned as a critical enabler of tumour-agnostic therapeutic development.
Newsletters and Deep Dive digital magazine
Liquid biopsy-based tools are positioned as a critical enabler of tumour-agnostic therapeutic development.
EVERSANA INTOUCH’s 2026 Pharma AI Overviews Report covers the rapid evolution within the Google AI Overviews landscape.
March and April offered no shortage of talking points for the clinical trials community.
Shauna Lord recently joined GSK as Business Unit Head Specialty (UK Commercial) to lead the Specialty business in the UK.
Veeva's Commercial Cloud aims to deliver the right medicines to more patients.
Editor's Picks
Newsletters and Deep Dive
digital magazine